Aparna Rao, Ph.D.
Affiliations: | 2012 | University of Pittsburgh, Pittsburgh, PA, United States |
Area:
OncologyGoogle:
"Aparna Rao"Parents
Sign in to add mentor| Walter J. Storkus | grad student | 2012 | University of Pittsburgh | |
| (Integration of HSP90 inhibition in combinational immunotherapies targeting receptor tyrosine kinase EphA2.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Zhang X, Kim WJ, Rao AV, et al. (2022) In vivo efficacy of decitabine as a natural killer cell-mediated immunotherapy against isocitrate dehydrogenase mutant gliomas. Neurosurgical Focus. 52: E3 |
| Ludwig N, Rao A, Sandlesh P, et al. (2021) Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles. Neuro-Oncology |
| Azambuja JH, Ludwig N, Yerneni S, et al. (2020) Molecular profiles and immunomodulatory activities of glioblastoma-derived exosomes. Neuro-Oncology Advances. 2: vdaa056 |
| Ludwig N, Rao A, Yerneni SS, et al. (2019) Isolation and characterization of exosomes from IDH mutant gliomas. Journal of Clinical Oncology. 37: 152-152 |
| Amankulor NM, Kim Y, Arora S, et al. (2017) Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes & Development |
| Rao A, Amankulor N. (2017) Natural Killer Cells in Cancer: An Overview Postdoc Journal. 5 |
| Rao A, Zhang X, Deibert C, et al. (2016) Abstract 3235: IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligands Cancer Research. 76: 3235-3235 |
| Rao A, Lowe DB, Storkus WJ. (2012) Shock block for improved immunotherapy. Oncoimmunology. 1: 1427-1429 |
| Rao A, Taylor JL, Chi-Sabins N, et al. (2012) Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells. Cancer Research. 72: 3196-206 |
| Bose A, Lowe DB, Rao A, et al. (2012) Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. Melanoma Research. 22: 236-43 |